MIRACOR OPERATIONAL UPDATE – FEBRUARY 2023
PRESSURE-CONTROLLED INTERMITTENT CORONARY OCCLUSION IMPROVES THE VASODILATORY MICROVASCULAR CAPACITY AND REDUCES MYOCARDIAL INJURY IN PATIENTS WITH STEMI.
Scarsini R, Terentes-Printzios D, Shanmuganathan M, Kotronias RA, Borlotti A, Marin F, Langrish J, Lucking A, Ribichini F; OxAMI Study, Kharbanda R, Ferreira VM, Channon KM, De Maria GL, Banning AP.
Miracor Announces FDA IDE Approval for PiCSO Pivotal Study.
Miracor Medical starts 2nd randomized study, targeting expanded indications.
Miracor Medical raises 24M€
Miracor Medical awarded CE Mark for PiCSO Impulse Catheter and Console
Miracor Medical announces PiCSO presentations during PCR e-Course
Miracor Medical granted FDA Breakthrough Device Designation for the PiCSO therapy
Miracor Medical starts PiCSO-AMI-I randomized study in EU
Miracor Medical closes final tranche of Series-D bringing the round to 30€M
Interview of Olivier Delporte, CEO Miracor Medical SA – interview in French
EuroPCR 2018 Presentations – Paris, France, May 25-22